Cargando…
Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132968/ https://www.ncbi.nlm.nih.gov/pubmed/35614047 http://dx.doi.org/10.1038/s41392-022-01022-x |